CBD and Alcohol Use Disorder: What Human Trials Show

CBD is being studied for alcohol use disorder (AUD), but it is not an established or FDA-approved treatment for the condition. Some small studies have found reduced craving, while others have found no benefit over placebo. Changes in brain activity do not, by themselves, show that a treatment helps people reduce drinking or maintain recovery.

What the Original Brain-Imaging Review Found

A 2024 systematic review examined 16 neuroimaging studies of CBD in healthy participants. It described effects involving GABA and glutamate signaling and brain networks associated with reward, emotion, and executive function.

The researchers used these findings to propose mechanisms that might be relevant to AUD. The review was not a clinical demonstration that CBD treats alcohol dependence: its healthy-participant imaging studies did not establish sustained reductions in drinking among people with AUD.

Newer Human Trials Give Mixed Results

The ICONIC randomized trial compared one 800-mg dose of CBD with placebo in 28 adults with AUD. Participants receiving CBD reported less craving during laboratory stress and alcohol-cue tasks, and imaging showed lower cue-related activity in the nucleus accumbens. These were short-term experimental outcomes, not evidence of lasting abstinence or fewer alcohol-related harms. The research dose is not a self-treatment recommendation.

An eight-week pilot study involving 44 participants compared full-spectrum CBD containing a small amount of THC, broad-spectrum CBD without THC, and placebo. The full-spectrum group showed improvements in craving and AUD symptom measures, but not in drinks per drinking day. Because that preparation also contained THC, its findings cannot be attributed to CBD alone or generalized to all CBD products.

More caution comes from two randomized proof-of-concept trials. One enrolled 27 adults with moderate-to-severe AUD for eight weeks; the other enrolled 30 adults with AUD and PTSD or subthreshold PTSD for six weeks. Neither demonstrated that CBD was better than placebo for drinking outcomes or craving. Seven of the 31 participants assigned to CBD experienced side effects that limited dosing.

These small studies leave uncertainty about which preparation, if any, could help and whether a benefit would persist. A reduction in laboratory craving is a reason for further investigation, not proof of an effective treatment.

Safety and Alcohol Withdrawal

The FDA identifies liver injury, medication interactions, and drowsiness among CBD’s risks. Combining CBD with alcohol or other substances that slow brain activity can increase sedation. Trial participants are screened and monitored; tolerability in a small research sample does not establish safety for everyone, especially someone with liver disease or multiple medications.

CBD is not a proven treatment for alcohol withdrawal. As NIAAA explains, withdrawal after sustained heavy drinking can be life-threatening. Seek medical advice before abruptly stopping if you may be physically dependent. Seizures, severe confusion, or hallucinations require urgent medical attention. Do not use CBD to attempt an unsupervised detox.

Treatments With Established Evidence

NIAAA describes evidence-based AUD care that includes behavioral treatment, medication, and mutual-support groups. The FDA-approved medications are naltrexone, acamprosate, and disulfiram. A clinician can help choose an approach based on drinking goals, medical conditions, current medicines, and withdrawal risk.

Our comparison of alcohol and marijuana risks provides broader context, but replacing alcohol with another substance is not equivalent to receiving AUD treatment. If you already use CBD, tell your clinician what product and amount you take so they can assess interactions and help you plan care.

CBD remains an investigational option for AUD. The most useful next step for someone seeking help is an individualized treatment plan, rather than assuming that a retail CBD product reproduces a research finding.